Home › Asahi Kasei Pharma Selects Evotec As Its Partner For Ion Channel Drug Discovery
 

Keywords :   


Asahi Kasei Pharma Selects Evotec As Its Partner For Ion Channel Drug Discovery

2015-04-01 08:17:32| drugdiscoveryonline Home Page

Evotec AG recently announced it has entered into a multi-target screening collaboration on several ion channel targets, with Asahi Kasei Pharma Corporation, a wholly owned subsidiary of Asahi Kasei Corporation, Tokyo, Japan. Under the terms of the agreement, Evotec will use its world-class ion channel platform to identify inhibitors of multiple ion channel targets

Tags: partner channel drug discovery

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
16.05Eastern North Pacific Tropical Weather Outlook
16.05Atlantic Tropical Weather Outlook
16.05The man who turned his dead father into a chatbot
16.05Firms leaving UK 'not a crisis' says stock market boss
15.05Exploring the future of agriculture
15.05American, Mexican, and Canadian cattle producers sign joint statement
15.05Attitudes EWG Verified Skincare Line Oceanly Expands with SPF Offerings
15.05Sherwin-Williams Packaging Coatings Expands Non-BPA Coatings Production in Europe
More »